SecBot SecBot
8-K ·Filed Apr 15, 2026

BCDA

BioCardia, Inc.
BEARISH
Impact 8/10
Horizonweeks Processed6mo ago SEC0001437749-26-012412
8-K context-dependent: Items 3.01
Actionable Insight ▼ Bearish

Monitor whether BioCardia can secure additional capital or execute a reverse stock split to regain compliance by October 7, 2026 (180 days from notice). Failure to submit an acceptable plan by May 25 could trigger immediate delisting proceedings.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
BCDA ▼ -23.51% at T+60d
SHORT call ✓ call won +23.51% · α vs SPY +30.56% · entry $1.19 → $0.9102
Entry = T+0 close
Apr 15, 2026
via day close
T+1d
-0.84%
call +0.84% · α +2.06%
$1.18
settled 6mo ago
T+5d
-1.68%
call +1.68% · α +2.66%
$1.17
settled 6mo ago
T+20d
-10.08%
call +10.08% · α +15.90%
$1.07
settled 6mo ago
T+60d
-23.51%
call +23.51% · α +30.56%
$0.9102
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

BioCardia received a Nasdaq delisting notice due to failing the $2.5 million minimum stockholders' equity requirement, with stockholders' equity at $895,000 as of December 31, 2025. The company has until May 25, 2026 to submit a compliance plan and may receive up to 180 days to regain compliance.

Key Facts

  • Received Nasdaq delisting notice for failing minimum stockholders' equity requirement of $2.5 million
  • Stockholders' equity was $895,000 as of December 31, 2025
  • Company has until May 25, 2026 to submit a compliance plan
  • Nasdaq may grant up to 180 calendar days from April 10, 2026 to regain compliance
  • Stock continues to trade on Nasdaq under symbol BCDA while the process unfolds

Financial Impact

Company's stockholders' equity of $895,000 is 64.2% below the $2.5 million Nasdaq minimum requirement

market valueliquidityinvestor confidence

Risk Factors

  • Delisting from Nasdaq which would reduce institutional ownership and liquidity
  • Potential inability to raise capital needed to meet equity requirements

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-012412
Document: 0001437749-26-012412-index-headers.html0001437749-26-012412
Document: 0001437749-26-012412-index.html0001437749-26-012412
Document: 0001437749-26-012412.txt0001437749-26-012412
27 reports for BCDA
Performance horizon
57% Hit rate @ T+1 8 of 14 directional calls Went positive at some point 11 of 14 best @ T+20▲ +30.43%May 28, 2026
Filters
Rows
Reports for BCDA — sortable, filterable
TypeNow
Oct 19, 2026
7d ago
8-K
BULLISH ★ 6/10
$0.8975 $1.04▲ +15.88%▲ +15.54%$0.9000 (+0.28%)
Oct 19, 2026
7d ago
Press Release
BULLISH ★ 6/10
$0.9000 $1.04▲ +15.56%▲ +15.22%$0.9000 (−0.00%)
Oct 7, 2026
19d ago
8-K
NEUTRAL ★ 3/10
$1.09 $1.06▼ −2.75%▼ −2.33%$0.9000 (−17.43%)
Oct 1, 2026
25d ago
8-K
NEUTRAL ★ 4/10
$1.02 $1.04▲ +1.96%▲ +1.22%$0.9000 (−11.76%)
Oct 1, 2026
25d ago
Press Release
BULLISH ★ 7/10
$1.02 $1.04▲ +1.96%▲ +1.22%$0.9000 (−11.76%)
Sep 23, 2026
4w ago
8-K
NEUTRAL ★ 3/10
$1.05 $1.07▲ +1.90%▲ +1.99%$0.9000 (−14.29%)
Sep 23, 2026
4w ago
Press Release
NEUTRAL ★ 4/10
$1.05 $1.07▲ +1.90%▲ +1.99%$0.9000 (−14.29%)
Sep 10, 2026
6w ago
8-K
NEUTRAL ★ 3/10
$1.10 $1.08▼ −1.82%▼ −2.67%$0.9000 (−18.18%)
Aug 24, 2026
9w ago
8-K
BULLISH ★ 6/10
$1.06 $1.13▲ +6.60%▲ +6.28%$0.9000 (−15.09%)
Aug 5, 2026
11w ago
Press Release
NEUTRAL ★ 1/10
$0.9500 $0.9496▼ −0.04%▲ +0.12%$0.9000 (−5.26%)
Showing 10 of 27

US Market Status

Market Closed — Opens in 3h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026